Article
Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective.
BMC cancer - 27 Mar 2018
Tan Ping-Tee, Aziz Mohamed Ismail Abdul, Pearce Fiona, Lim Wan-Teck, Wu David Bin-Chia, Ng Kwong
Abstract excerpt
BACKGROUND: Non-small-cell lung cancer (NSCLC) accounts for 85% of all lung cancers and is associated with a poor prognosis. Afatinib is an irreversible ErbB family blocker recommended in clinical guidelines as a first-line treatment for NSCLC which harbours an epidermal growth factor receptor (EGFR) mutation. The objective of this study was to evaluate the cost-effectiveness of afatinib versus...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.